Several tyrosine kinase inhibitors (TKIs), including first-generation FLT3 inhibitors such as tandutinib, sunitinib, midostaurin, lestaurtinib and sorafenib, have been developed as valuable therapeutic agents for prolonging overall survival in AML patients [8–12]. The gene discussed is FLT3; the disease is acute myeloid leukemia.